Mabion receives FDA confirmation for Pre-IND Type B meeting
Mabion said the FDA confirmed a Pre-IND Type B meeting for MabionCD20, seeking orphan drug status in ITP.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.